Showing results (541-550 of 564) with videos related to

Sort By:
Pageof 57
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2019
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trialD Moro-Sibilot, N Cozic, M Pérol, et al.
Antimicrobial Agents and Chemotherapy|June 3, 2010
PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replicationAngela M Lam, Eisuke Murakami, Christine Espiritu, et al.
Chemistry & Biology|April 1, 1996
Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450C N Hodge, P E Aldrich, L T Bacheler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutationsJ Mazieres, C Cropet, L Montané, et al.
Cancers|October 23, 2021
Reinspection of a Clinical Proteomics Tumor Analysis Consortium (CPTAC) Dataset with Cloud Computing Reveals Abundant Post-Translational Modifications and Protein Sequence VariantsAmol Prakash, Lorne Taylor, Manu Varkey, et al.
The New England Journal of Medicine|August 17, 2012
Quality-of-life effects of prostate-specific antigen screeningEveline A M Heijnsdijk, Elisabeth M Wever, Anssi Auvinen, et al.
Thyroid : Official Journal of the American Thyroid Association|July 22, 2020
Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS MutationsJuan C Hernandez-Prera, Pablo Valderrabano, Jordan H Creed, et al.
Research Square|July 28, 2023
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerChang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Nature Communications|March 14, 2024
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerChang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
JSES International|December 21, 2020
The modern reverse shoulder arthroplasty and an updated systematic review for each complication: part ISarav S Shah, Benjamin T Gaal, Alexander M Roche, et al.
Pageof 57